Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays

키워드

참고문헌 (45)

1. El-Serag HB, "Hepatocellular carcinoma: an epidemiologic view", J Clin Gastroenterol, 35(5 Suppl 2), pp.S72~S78 (2002)[DOI]
2. Davila JA, "Cholangiocarcinoma: the other liver cancer on the rise", Am J Gastroenterol, 97, pp.3199~3200 (2002)
3. McGlynn KA, "International trends and patterns of primary liver cancer", Int J Cancer, 94, pp.290~296 (2001)[DOI]
4. El-Serag HB, "Hepatocellular carcinoma: epidemiology and molecular carcinogenesis", Gastroenterology, 132, pp.2557~2576 (2007)[DOI]
5. Yao FY, "A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy", Liver Transpl, 9, pp.684~692 (2003)[DOI]
6. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)[DOI]
7. Valle JW, "Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study", Br J Cancer, 101, pp.621~627 (2009)[DOI]
8. Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)[DOI]
9. European Association for the Study of the Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)[DOI]
10. Kim SA, "Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern--correlation with clinicopathologic findings", Radiology, 260, pp.148~157 (2011)[DOI]
11. Kang Y, "Intrahepatic massforming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images", Radiology, 264, pp.751~760 (2012)[DOI]
12. Nanashima A, "Intrahepatic cholangiocarcinoma: relationship between tumor imaging enhancement by measuring attenuation and clinicopathologic characteristics", Abdom Imaging, 38, pp.785~792 (2013)[DOI]
13. Radwan NA, "The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1", Diagn Pathol, 7, pp.149~ (2012)[DOI]
14. Lamps LW, "The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review", Adv Anat Pathol, 10, pp.39~43 (2003)[DOI]
15. Kakar S, "Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms", Arch Pathol Lab Med, 131, pp.1648~1654 (2007)
16. Chu PG, "Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alphafetoprotein", Am J Surg Pathol, 26, pp.978~988 (2002)[DOI]
17. Kakar S, "Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma", Am J Clin Pathol, 119, pp.361~366 (2003)[DOI]
18. Minervini MI, "Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors", Mod Pathol, 10, pp.686~692 (1997)
19. Lok AS, "Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma", Gastroenterology, 138, pp.493~502 (2010)[DOI]
20. Marrelli D, "CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions", Am J Surg, 198, pp.333~339 (2009)[DOI]
21. Man XB, "Upregulation of glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers", Liver Int, 25, pp.962~966 (2005)[DOI]
22. Wang L, "Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset", Tumour Biol, 34, pp.1679~1684 (2013)[DOI]
23. Heringlake S, "Identification and expression analysis of the aldoketoreductase1-B10 gene in primary malignant liver tumours", J Hepatol, 52, pp.220~227 (2010)[DOI]
24. Hass HG, "Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis", World J Gastroenterol, 14, pp.2501~2510 (2008)[DOI]
25. Rajeevan MS, "Validation of array-based gene expression profiles by real-time (kinetic) RTPCR", J Mol Diagn, 3, pp.26~31 (2001)[DOI]
26. Ganjei P, "Histologic markers in primary and metastatic tumors of the liver", Cancer, 62, pp.1994~1998 (1988)[DOI]
27. Fujiwara M, "Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies", Cancer Cytopathol, 120, pp.230~237 (2012)[DOI]
28. Rullier A, "Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis", Am J Surg Pathol, 24, pp.870~876 (2000)[DOI]
29. Sugiki T, "Specific characteristics of scirrhous hepatocellular carcinoma", Hepatogastroenterology, 56, pp.1086~1089 (2009)
30. Gambarin-Gelwan M, "Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation", Am J Gastroenterol, 95, pp.1535~1538 (2000)[DOI]
31. Hass HG, "Diagnostic and prognostic aspects of hepatocellular carcinoma: a retrospective analysis in 145 patients", J Gastroenterol Hepatol Res, 6, pp.2358~2364 (2017)[DOI]
32. Kokudo N, "Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines", J Gastroenterol, 44(Suppl 19), pp.119~121 (2009)[DOI]
33. Durnez A, "The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: a possible progenitor cell origin", Histopathology, 49, pp.138~151 (2006)[DOI]
34. Uenishi T, "Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence", Cancer Sci, 94, pp.851~857 (2003)[DOI]
35. Park SY, "Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary", Hum Pathol, 33, pp.1078~1085 (2002)[DOI]
36. Ahopelto K, "Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer", Cancer Biol Ther, 17, pp.163~168 (2016)[DOI]
37. Tan GS, "Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients", J Proteome Res, 13, pp.4833~4846 (2014)[DOI]
38. Corona G, "Differential proteomic analysis of hepatocellular carcinoma", Int J Oncol, 36, pp.93~99 (2010)
39. Cheng W, "Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: potential for therapy", Mol Med Rep, 12, pp.2451~2456 (2015)[DOI]
40. Kobayashi H, "A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade", J Biol Chem, 278, pp.7790~7799 (2003)[DOI]
41. Bullard RS, "Functional analysis of the host defense peptide human beta defensin-1: new insight into its potential role in cancer", Mol Immunol, 45, pp.839~848 (2008)[DOI]
42. Arimura Y, "Elevated serum betadefensins concentrations in patients with lung cancer", Anticancer Res, 24, pp.4051~4057 (2004)
43. Sirnes S, "Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome", Int J Cancer, 131, pp.570~581 (2012)[DOI]
44. Elzarrad MK, "Connexin-43 upregulation in micrometastases and tumor vasculature and its role in tumor cell attachment to pulmonary endothelium", BMC Med, 6, pp.20~ (2008)[DOI]
45. Xue TC, "Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis", Tumour Biol, 36, pp.5891~5899 (2015)[DOI]

관련 논문AI추천